hotspot -WSS

hotspot

author：hotspot 2025-10-01 22:49:13 - browse：3

The experimental Alzheimer’s drug lecanemab, hailed after it slowed patients’ cognitive decline in a clinical trial, may have contributed to the death in June of a patient in the study, STAT has learned.

One investigator on the study flagged the death, noting it came after the patient experienced bleeding in the brain, and concluded it was related to the drug, according to documents obtained by STAT. Eisai, the drugmaker behind lecanemab, disagreed, pointing to other possible factors, including a series of setbacks in preceding months — multiple falls, a heart attack, a respiratory infection, and mini-stroke-like events.

Though still under investigation, the death suggests that new medicines to treat Alzheimer’s, like medicines to treat anything else, will come with their own side effects and costs. It also raises the importance of waiting for the full lecanemab data before drawing conclusions based on the positive press release put out by Eisai and its partner Biogen last month.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Medical records are filled with copy
Next article： FDA approves first new drug developed for postpartum depression

WSS

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

RSV shot was 90% effective at preventing hospitalizations in kids

Senate panel passes drug pricing bills, but drops one PBM reform

Millions may soon lose Medicaid when they don't have to

In his State of the Union, Biden takes clear aim at 'Big Pharma'

Change Healthcare payments predicted restored March 15

Wikipedia

hotspot

focus

Heart attack and stroke risk calculators need revising

Timeline: Key moments in fight for gay rights

Anesthesiologist group: stop taking Ozempic before surgery

Former medical device CEO who sold dummy, plastic parts convicted of fraud

Continuity nursing helped my family in our darkest PICU moments

In surprise move, FDA calls for advisory committee on Lilly's Alzheimer's drug

Trump demands the U.S. pay no more for drugs than other countries … again

Headspace, Meta partner to launch VR meditation app for Quest

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Pioneering cancer drug will cost $475,000. Analysts call it a bargain

focus

Sen. Paul opposes bill to ban Chinese biotechs

Patients, doctors are clashing about side effects of hormonal birth control

Novo Nordisk obesity pill bests Wegovy in early trial

Former medical device CEO who sold dummy, plastic parts convicted of fraud

FDA approves first new drug developed for postpartum depression

The Readout: Amylyx, Alumis, and Lundbeck drug updates

knowledge

focus

focus

explore